Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...

Shares of Gilead Sciences Inc. GILD inched 0.04% higher to $92.38 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6 ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...

Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.